Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, according to a study published online Oct. 16 in ...

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks ... The study was funded by the Merck Investigator ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

A subgroup analysis found that pembrolizumab plus chemotherapy improved disease-free survival in high-risk patients with ...

a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck ...

Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...